4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immunotech Biopharm Ltd (6978) operates in the Biotechnology industry and is headquartered in Beijing, China with about 189 employees. Its market capitalization is roughly HK$244 million. In the fiscal year ended 2025-12-31, 6978 reported CNY 0M in revenue and (CNY 231M) in net income.
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 0M | CNY 0M | CNY 0M | CNY 0M | — |
| Operating Income (EBIT) | (CNY 156M) | (CNY 169M) | (CNY 224M) | (CNY 269M) | — |
| Net Income | (CNY 231M) | (CNY 187M) | (CNY 335M) | (CNY 318M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 603M | CNY 564M | CNY 846M | CNY 879M | — |
| Total Liabilities | CNY 620M | CNY 580M | CNY 675M | CNY 373M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6978 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms